Pierre-Francois Laterre - JoVE Visualize

Showing results (11-20 of 36) with videos related to

Pageof 4

Sort By:

International Journal of Antimicrobial Agents|July 30, 2020

What is the optimal loading dose of broad-spectrum β-lactam antibiotics in septic patients? Results from pharmacokinetic simulation modellingIsabelle K Delattre, Maya Hites, Pierre-Francois Laterre, et al.

Critical Care Medicine|January 11, 2005

Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trialPierre-Francois Laterre, Howard Levy, Gilles Clermont, et al.

ERJ Open Research|January 11, 2023

Circulating dipeptidyl peptidase 3 and bio-adrenomedullin levels are associated with impaired outcomes in critically ill COVID-19 patients: a prospective international multicentre studyDirk van Lier, Benjamin Deniau, Karine Santos, et al.

Critical Care Medicine|January 11, 2005

The effect of drotrecogin alfa (activated) on long-term survival after severe sepsisDerek C Angus, Pierre-Francois Laterre, Jeff Helterbrand, et al.

Critical Care (London, England)|August 16, 2017

Selepressin, a novel selective vasopressin V<sub>1A</sub> agonist, is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patientsJames A Russell, Jean-Louis Vincent, Anne Louise Kjølbye, et al.

Critical Care Medicine|December 16, 2004

Sources of variability on the estimate of treatment effect in the PROWESS trial: implications for the design and conduct of future studies in severe sepsisWilliam L Macias, Benoit Vallet, Gordon R Bernard, et al.

Journal of Critical Care|June 6, 2007

International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: 28-day survival and safetyPierre-Francois Laterre, David R Nelson, William Macias, et al.

Critical Care (London, England)|March 18, 2004

Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569]Gary T Kinasewitz, S Betty Yan, Bruce Basson, et al.

Critical Care Medicine|May 14, 2005

Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS studyPierre-Francois Laterre, Gary Garber, Howard Levy, et al.

Critical Care (London, England)|March 10, 2011

Multinational, observational study of procalcitonin in ICU patients with pneumonia requiring mechanical ventilation: a multicenter observational studyFrank Bloos, John C Marshall, Richard P Dellinger, et al.

Pageof 4

Showing results (11-20 of 36) with videos related to

Sort By:

Pageof 4

International Journal of Antimicrobial Agents|July 30, 2020

What is the optimal loading dose of broad-spectrum β-lactam antibiotics in septic patients? Results from pharmacokinetic simulation modellingIsabelle K Delattre, Maya Hites, Pierre-Francois Laterre, et al.

Critical Care Medicine|January 11, 2005

Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trialPierre-Francois Laterre, Howard Levy, Gilles Clermont, et al.

ERJ Open Research|January 11, 2023

Circulating dipeptidyl peptidase 3 and bio-adrenomedullin levels are associated with impaired outcomes in critically ill COVID-19 patients: a prospective international multicentre studyDirk van Lier, Benjamin Deniau, Karine Santos, et al.

Critical Care Medicine|January 11, 2005

The effect of drotrecogin alfa (activated) on long-term survival after severe sepsisDerek C Angus, Pierre-Francois Laterre, Jeff Helterbrand, et al.

Critical Care (London, England)|August 16, 2017

Selepressin, a novel selective vasopressin V<sub>1A</sub> agonist, is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patientsJames A Russell, Jean-Louis Vincent, Anne Louise Kjølbye, et al.

Critical Care Medicine|December 16, 2004

Sources of variability on the estimate of treatment effect in the PROWESS trial: implications for the design and conduct of future studies in severe sepsisWilliam L Macias, Benoit Vallet, Gordon R Bernard, et al.

Journal of Critical Care|June 6, 2007

International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: 28-day survival and safetyPierre-Francois Laterre, David R Nelson, William Macias, et al.

Critical Care (London, England)|March 18, 2004

Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569]Gary T Kinasewitz, S Betty Yan, Bruce Basson, et al.

Critical Care Medicine|May 14, 2005

Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS studyPierre-Francois Laterre, Gary Garber, Howard Levy, et al.

Critical Care (London, England)|March 10, 2011

Multinational, observational study of procalcitonin in ICU patients with pneumonia requiring mechanical ventilation: a multicenter observational studyFrank Bloos, John C Marshall, Richard P Dellinger, et al.

Pageof 4